Table 3.
Tumorigenesis in Pten +/− ± TgFSH females. Summary of tumour types and incidence (number affected in whole group and shown as %) in the indicated tissues of Pten +/− and FPten +/− mice.
| Pten+/− (%) | FPten+/− (%) | |
|---|---|---|
| Endometrium | ||
| NAD | 10/31 (32) | 10/27 (37) |
| Polyps | 3/31 (10) | 3/27 (11) |
| Metaplasia | 4/31 (13) | 0/27 (0) |
| Hyperplasia | 0/31 (0) | 2/27 (7) |
| Dysplasia | 7/31 (23) | 6/27 (22) |
| Endometrial adenoma | 2/31 (6) | 1/27 (4) |
| Endometrial adenocarcinoma | 0/31 (0) | 1/27 (4) |
| Endometrial choriocarcinoma | 5/31 (16) | 4/27 (15) |
| Mammary | ||
| NAD | 26/31(84) | 21/27 (78) |
| Mammary adenoma | 1/31 (3) | 3/27 (11) |
| Mammary adenocarcinoma | 3/31 (10) | 2/27 (7) |
| Fibroadenoma | 1/31 (3) | 1/27 (4) |
| Adrenal | ||
| NAD | 30/31 (97) | 21/27 (78) |
| Adrenocortical nodular hyperplasia | 1/31 (3) | 6/27 (22) |
| Lymph | ||
| NAD | 28/31 (90) | 24/27 (89) |
| Lymphosarcoma | 3/31 (10) | 3/27 (11) |
| Pituitary | ||
| NAD | 25/31 (81) | 19/27 (70) |
| Pituitary adenoma | 6/31 (19) | 8/27 (30) |
NAD no abnormalities detected